Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Mountainfield Venture Partners is a venture capital firm based in the United States, founded by a team with extensive biopharmaceutical leadership experience. The firm focuses on building new companies around development-stage drug candidates and has co-founded over 15 venture-backed life sciences companies. Their portfolio includes six NASDAQ IPOs and eight FDA-approved drug products.
This firm invests in the biopharmaceutical sector, specifically targeting development-stage drug candidates. Mountainfield primarily invests at the seed, Series A, and Series B stages, emphasizing the creation of companies that leverage in-licensed drug candidates and operational strategies informed by their team's extensive industry experience.
Notable companies in Mountainfield's portfolio include Myovant (NASDAQ: MYOV), Phathom Pharmaceuticals (NASDAQ: PHAT), Day One Pharmaceuticals (NASDAQ: DAWN), Arcutis (NASDAQ: ARQT), HilleVax (NASDAQ: HLVX), and Passage Bio (NASDAQ: PASG). These companies have collectively led to six NASDAQ IPOs and eight FDA-approved drug products.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.